Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)

被引：4

作者：

Sakata, Yoshihiko ^{[1
]}

Saito, Go ^{[2
]}

Sakata, Shinya ^{[3
]}

Oya, Yuko ^{[4
,5
]}

Tamiya, Motohiro ^{[6
]}

Suzuki, Hidekazu ^{[7
]}

Shibaki, Ryota ^{[8
]}

Okada, Asuka ^{[9
]}

Yokoyama, Toshihide ^{[10
]}

Matsumoto, Hirotaka ^{[11
]}

Otsuki, Taiichiro ^{[12
]}

Sato, Yuki ^{[13
]}

Junji, Uchida ^{[14
]}

Tsukita, Yoko ^{[15
]}

Inaba, Megumi ^{[16
]}

Ikeda, Hideki ^{[2
,17
]}

Arai, Daisuke ^{[18
]}

Maruyama, Hirotaka ^{[19
]}

Hara, Satoshi ^{[20
]}

Tsumura, Shinsuke ^{[21
]}

Morinaga, Jun ^{[22
]}

Sakagami, Takuro ^{[3
]}

机构：

[1] Saiseikai Kumamoto Hosp, Div Resp Med, 5-3-1 Chikami,Minami Ku, Kumamoto 8614193, Japan

[2] Chiba Univ, Grad Sch Med, Dept Respirol, 1-8-1 Inohana,Chuo Ku, Chiba, Chiba 2608670, Japan

[3] Kumamoto Univ Hosp, Dept Resp Med, 1-1-1 Honjo,Chuo Ku, Kumamoto 8608556, Japan

[4] Aichi Canc Ctr Hosp, Dept Thorac Oncol, 1-1 Kanokoden,Chikusa Ku, Nagoya, Aichi 4648681, Japan

[5] Fujita Hlth Univ, Sch Med, Dept Resp Med, Kutsukake Cho, Toyoake, Aichi 4701192, Japan

[6] Osaka Int Canc Inst, Dept Thorac Oncol, 3-1-69 Otemae,Chuo Ku, Osaka, Osaka 5418567, Japan

[7] Osaka Habikino Med Ctr, Dept Thorac Oncol, 3-7-1 Habikino, Habikino, Osaka 5838588, Japan

[8] Wakayama Med Univ, Internal Med 3, 811-1 Kimiidera, Wakayama, Wakayama 6418509, Japan

[9] Osaka City Gen Hosp, Dept Med Oncol, 2-13-22 Miyakojima Hondori,Miyakojima Ku, Osaka 5340021, Japan

[10] Kurashiki Cent Hosp, Dept Resp Med, 1-1-1 Miwa, Kurashiki, Okayama 7108602, Japan

[11] Hyogo Prefectural Amagasaki Gen Med Ctr, Dept Resp Med, 2-17-77 Higashinaniwa, Amagasaki, Hyogo 6608550, Japan

[12] Hyogo Med Univ, Dept Resp Med & Hematol, Sch Med, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan

[13] Kobe City Med Ctr Gen Hosp, Dept Resp Med, 2-1-1 Minatojimaminami,Chuo Ku, Kobe, Hyogo 6500047, Japan

[14] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, 5-1-1 Toneyama, Toyonaka, Osaka 5608552, Japan

[15] Tohoku Univ, Grad Sch Med, Dept Resp Med, 1-1 Seiryo,Aoba Ku, Sendai, Miyagi 9808574, Japan

[16] Kumamoto City Hosp, Div Resp Med, 1-5-1 Tainoshima,Minami Ku, Kumamoto 8620965, Japan

[17] Kimitsu Chuo Hosp, Dept Resp Med, 1010 Sakurai, Kisarazu, Chiba 2928535, Japan

[18] Saiseikai Utsunomiya Hosp, Dept Internal Med, 911-1 Takebayashi, Utsunomiya, Tochigi 3210974, Japan

[19] Kumamoto Rosai Hosp, Dept Resp Med, Japan Org Occupat Hlth & Safety, 1670 Takehara, Yatsushiro, Kumamoto 8668533, Japan

[20] Itami City Hosp, Dept Resp Med, 1-100 Koyaike, Itami, Hyogo 6648540, Japan

[21] Kumamoto Reg Med Ctr, Dept Resp Med, 5-16-10 Honjo,Chuo Ku, Kumamoto 8600811, Japan

[22] Kumamoto Univ Hosp, Dept Clin Invest Biostat, 1-1-1 Honjo,Chuo Ku, Kumamoto 8608556, Japan

来源：

LUNG CANCER | 2023年 / 186卷

关键词：

Non-small cell lung cancer; EGFR mutation; First-line therapy; Osimertinib; Elderly; Real world; FACTOR RECEPTOR MUTATIONS; OPEN-LABEL; PHASE-II; GEFITINIB; CHEMOTHERAPY; MULTICENTER; ERLOTINIB; AFATINIB;

D O I：

10.1016/j.lungcan.2023.107426

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Osimertinib is the primary treatment for patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer. However, evidence of the outcomes of osimertinib treatment in patients over 75 years of age in the real-world setting is limited.Materials and Methods: This retrospective study analyzed the data of 538 patients (203 elderly and 335 non -elderly) with EGFR mutation-positive lung cancer in whom osimertinib was initiated as first-line treatment between August 2018 and December 2019. Patients over 75 years of age were classified as elderly. The data cut-off date was February 28, 2022.Results: The progression-free survival (PFS) did not significantly differ between the elderly and non-elderly groups [elderly group: median PFS, 16.9 months (95 % confidence interval (CI), 14.3-20.2); non-elderly group: median PFS, 22.1 months (95 % CI: 19.5-26.3); hazard ratio (HR) for the elderly against the non -elderly: 1.21 (95 % CI: 0.98-1.50), p = 0.079]. However, the time to treatment failure (TTF) was significantly shorter in the elderly than in the non-elderly [elderly group: median TTF, 14.0 months (95 % CI: 0.98-1.50); non -elderly group: median TTF, 21.8 months (95 % CI: 18.2-24.6); HR for the elderly against the non-elderly: 1.46 (95 % CI: 1.20-1.77), p < 0.001]. Furthermore, the rate of treatment discontinuation because of adverse events was 28.6 % in the elderly and 14.9 % in the non-elderly (p < 0.001). Among patients who discontinued treat-ment, the conversion rate to second-line treatment was 39.6 % in the elderly and 72.8 % in the non-elderly. In addition, the median overall survival was 30 months (95 % CI: 25.8-37.7) in the elderly and not reached (NR) (95 % CI: NR-NR) in the non-elderly (p < 0.001).Conclusion: In a real-world clinical setting, elderly patients receiving osimertinib as first-line treatment should be aware of the frequent inability to transition to second-line treatment due to adverse events.

引用

页数：10

共 50 条

[21] A multicentre, real-world observational study of efficacy and safety of first-line osimertinib treatment in patients with epidermal growth factor receptor (EGFR) activating mutation-positive advanced non-small cell lung cancer (Reiwa study)
Fukui, T.
Naoki, K.
Yoh, K.
Usui, K.
Hosomi, Y.
Kishi, K.
Naka, G.
Watanabe, K.
Uemura, K.
Kunitoh, H.
ANNALS OF ONCOLOGY, 2022, 33 : S1583 - S1584
[22] Real-World Experience of First-Line Afatinib Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
Liam, C.
Ho, G.
Chai, C.
Alip, A. Bt
Pang, Y.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S998 - S999
[23] Osimertinib in the Treatment of EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer: A Meta-Analysis
Pan, Jie
Cai, Xiaoping
Cao, Zhuo
Pan, Jiongwei
Zheng, Hao
PHARMACOLOGY, 2023, 108 (01) : 8 - 16
[24] First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
Igawa, Satoshi
Fukui, Tomoya
Kasajima, Masashi
Ono, Taihei
Ozawa, Takahiro
Kakegawa, Mikiko
Kusuhara, Seiichiro
Sato, Takashi
Nakahara, Yoshiro
Hisashi, Mitsufuji
Sasaki, Jiichiro
Naoki, Katsuhiko
INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) : 430 - 437
[25] First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study
Satoshi Igawa
Tomoya Fukui
Masashi Kasajima
Taihei Ono
Takahiro Ozawa
Mikiko Kakegawa
Seiichiro Kusuhara
Takashi Sato
Yoshiro Nakahara
Mitsufuji Hisashi
Jiichiro Sasaki
Katsuhiko Naoki
Investigational New Drugs, 2022, 40 : 430 - 437
[26] Impact of afatinib dosing on safety and efficacy in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) in a real-world setting
Halmos, Balazs
Tan, Eng-Huat
Soo, Ross
Cadranel, Jacques
Lee, Min Ki
Foucher, Pascal
Hsia, Te-Chun
Hochmair, Maximilian
Griesinger, Frank
Hida, Toyoaki
Kim, Edward
Melosky, Barbara
Maerten, Angela
Carcereny, Enric
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 160 - 161
[27] First-line treatment and overall survival in EGFR mutation-positive advanced non-small cell lung cancer: a national cohort study
Huang, L. -y.
Chang, H. -p.
Chang, R. -y.
Tai, H. -y.
Huang, Y. -w.
Lee, P. -c.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (20) : 7632 - 7640
[28] Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
Liang, Sheng-Kai
Hsieh, Min-Shu
Lee, Meng-Rui
Keng, Li-Ta
Ko, Jen-Chung
Shih, Jin-Yuan
ONCOTARGET, 2017, 8 (52) : 90430 - 90443
[29] Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
Schuler, A.
Huser, J.
Schmid, S.
Schar, S.
Scherz, A.
Gautschi, O.
Mauti, L.
von Briel, T.
Waibel, C.
Pankovics, J.
Mark, M. T.
Rothschild, S. I.
Addeo, A.
Janthur, W. D.
Siano, M.
Boos, L.
Britschgi, C.
Fruh, M.
LUNG CANCER, 2024, 187
[30] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
Park, Keunchil
Bennouna, Jaafar
Boyer, Michael
Hida, Toyoaki
Hirsh, Vera
Kato, Terufumi
Lug, Shun
Mok, Tony
Nakagawa, Kazuhiko
O'Byrne, Kenneth
Paz-Ares, Luis
Schuler, Martin
Sibilotru, Denis Moro
Tan, Eng-Huat
Tanaka, Hiroshi
We, Yi-Long
Yang, James C-H
Zhang, Li
Zhou, Caicun
Maerten, Angela
Tang, Wenbo
Yamamoto, Nobuyuki
LUNG CANCER, 2019, 132 : 126 - 131

← 1 2 3 4 5 →